219 related articles for article (PubMed ID: 30718976)
1. Establishment and characterization of a patient-derived circulating lung tumor cell line in vitro and in vivo.
Que Z; Luo B; Zhou Z; Dong C; Jiang Y; Wang L; Shi Q; Tian J
Cancer Cell Int; 2019; 19():21. PubMed ID: 30718976
[TBL] [Abstract][Full Text] [Related]
2. Jinfukang regulates integrin/Src pathway and anoikis mediating circulating lung cancer cells migration.
Que ZJ; Yang Y; Liu HT; Shang-Guan WJ; Yu P; Zhu LH; Li HG; Liu HM; Tian JH
J Ethnopharmacol; 2021 Mar; 267():113473. PubMed ID: 33068649
[TBL] [Abstract][Full Text] [Related]
3. Jinfukang inhibits lung cancer metastasis by upregulating CX3CL1 to recruit NK cells to kill CTCs.
Que ZJ; Yao JL; Zhou ZY; Yu P; Luo B; Li HG; Liu JX; Xu HX; Tian JH
J Ethnopharmacol; 2021 Jul; 275():114175. PubMed ID: 33933571
[TBL] [Abstract][Full Text] [Related]
4. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine inhibits the micrometastasis of non-small cell lung cancer by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway.
Liao ZJ; Guo YH; Zhao Z; Yao JT; Xu R; Nan KJ
Int J Oncol; 2014 Aug; 45(2):651-8. PubMed ID: 24867356
[TBL] [Abstract][Full Text] [Related]
6. High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients.
Zeinali M; Lee M; Nadhan A; Mathur A; Hedman C; Lin E; Harouaka R; Wicha MS; Zhao L; Palanisamy N; Hafner M; Reddy R; Kalemkerian GP; Schneider BJ; Hassan KA; Ramnath N; Nagrath S
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31947893
[TBL] [Abstract][Full Text] [Related]
7. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
[TBL] [Abstract][Full Text] [Related]
8. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
[TBL] [Abstract][Full Text] [Related]
9. Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer.
Ramani VC; Lemaire CA; Triboulet M; Casey KM; Heirich K; Renier C; Vilches-Moure JG; Gupta R; Razmara AM; Zhang H; Sledge GW; Sollier E; Jeffrey SS
Breast Cancer Res; 2019 Aug; 21(1):98. PubMed ID: 31462307
[TBL] [Abstract][Full Text] [Related]
10. Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
Bian J; Yan K; Liu N; Xu X
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2621-2630. PubMed ID: 32661602
[TBL] [Abstract][Full Text] [Related]
11. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF
Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126
[TBL] [Abstract][Full Text] [Related]
12. Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients.
Acheampong E; Morici M; Abed A; Bowyer S; Asante DB; Lin W; Millward M; Gray ES; Beasley AB
J Cancer Res Clin Oncol; 2023 May; 149(5):1941-1950. PubMed ID: 35896898
[TBL] [Abstract][Full Text] [Related]
13. Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients.
Togo S; Katagiri N; Namba Y; Tulafu M; Nagahama K; Kadoya K; Takamochi K; Oh S; Suzuki K; Sakurai F; Mizuguchi H; Urata Y; Takahashi K
Oncotarget; 2017 May; 8(21):34884-34895. PubMed ID: 28432274
[TBL] [Abstract][Full Text] [Related]
14. Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence.
Garcia J; Barthelemy D; Geiguer F; Ballandier J; Li KW; Aurel JP; Le Breton F; Rodriguez-Lafrasse C; Manship B; Couraud S; Payen L
J Vis Exp; 2019 Aug; (150):. PubMed ID: 31475991
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
[TBL] [Abstract][Full Text] [Related]
16. Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin.
Po JW; Roohullah A; Lynch D; DeFazio A; Harrison M; Harnett PR; Kennedy C; de Souza P; Becker TM
J Circ Biomark; 2018; 7():1849454418782617. PubMed ID: 30013673
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.
Blassl C; Kuhlmann JD; Webers A; Wimberger P; Fehm T; Neubauer H
Mol Oncol; 2016 Aug; 10(7):1030-42. PubMed ID: 27157930
[TBL] [Abstract][Full Text] [Related]
18. Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients.
Krawczyk N; Neubacher M; Meier-Stiegen F; Neubauer H; Niederacher D; Ruckhäberle E; Mohrmann S; Hoffmann J; Kaleta T; Banys-Paluchowski M; Reinecke P; Esposito I; Janni W; Fehm T
BMC Cancer; 2019 Nov; 19(1):1101. PubMed ID: 31718606
[TBL] [Abstract][Full Text] [Related]
19. Efficient isolation and quantification of circulating tumor cells in non-small cell lung cancer patients using peptide-functionalized magnetic nanoparticles.
Liang N; Liu L; Li P; Xu Y; Hou Y; Peng J; Song Y; Bing Z; Wang Y; Wang Y; Jia Z; Yang X; Li D; Xu H; Yu Q; Li S; Hu Z; Yang Y
J Thorac Dis; 2020 Aug; 12(8):4262-4273. PubMed ID: 32944338
[TBL] [Abstract][Full Text] [Related]
20. CTC-Derived Models: A Window into the Seeding Capacity of Circulating Tumor Cells (CTCs).
Tayoun T; Faugeroux V; Oulhen M; Aberlenc A; Pawlikowska P; Farace F
Cells; 2019 Sep; 8(10):. PubMed ID: 31557946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
